Volume 30, Number 8—August 2024
Synopsis
Systematic Review of Prevalence of Histoplasma Antigenuria in Persons with HIV in Latin America and Africa
Table
Characteristics of Histoplasma urine antigen prevalence studies included in systematic review of prevalence of Histoplasma antigenuria in persons with HIV in Latin America and Africa*
Reference | Country | Study design | Study population† | Clinical status | Setting | Test type‡ | No. participants | No. samples tested | HUA positivity, % |
---|---|---|---|---|---|---|---|---|---|
(14) |
Tanzania |
Cross-sectional |
All HIV and non-HIV |
Symptomatic |
Inpatient |
MV EIA |
628 |
628 |
1.1 |
(15) |
Uganda |
Cohort |
Advanced HIV |
Asymptomatic |
Outpatient |
IMMY GM EIA |
388 |
388 |
1.0 |
(16) |
Uganda |
Cohort |
Advanced HIV/meningitis |
Symptomatic |
Inpatient |
MV EIA |
257 |
257 |
0.0 |
(17) |
South Africa |
Cross-sectional |
Advanced HIV |
Symptomatic |
Outpatient |
IMMY Alpha EIA |
34 |
17 |
23.5 |
(18) |
South Africa |
Cross-sectional |
Advanced HIV |
Asymptomatic |
Inpatient |
IMMY GM EIA |
189 |
189 |
5.8 |
(19) |
Cameroon |
Cross-sectional |
All HIV |
Asymptomatic |
Outpatient |
OIDx EIA |
138 |
138 |
26.1 |
(20) |
Ghana |
Cross-sectional |
All HIV |
Asymptomatic |
Outpatient |
IMMY GM EIA + OIDx LFA |
150 |
107 |
5.6 |
(21) |
Nigeria |
Cross-sectional |
Advanced HIV |
Symptomatic |
Outpatient |
IMMY GM EIA |
213 |
41 |
7.3 |
(22) |
Nigeria |
Cross-sectional |
Advanced HIV |
Symptomatic |
Inpatient |
IMMY GM EIA |
988 |
988 |
7.7 |
(23) |
Mexico |
Cohort |
Advanced HIV |
Symptomatic |
Inpatient |
IMMY Alpha EIA |
288 |
288 |
21.5 |
(24) |
Brazil |
Cohort |
Advanced HIV |
Asymptomatic |
Inpatient |
IMMY Alpha EIA |
106 |
106 |
3.8 |
(25) |
Colombia |
Cross- sectional |
Advanced HIV |
Symptomatic |
Inpatient |
IMMY Alpha EIA |
172 |
172 |
29.1 |
(26) |
Colombia |
Cross-sectional |
Advanced HIV |
Asymptomatic |
Outpatient |
CDC ELISA |
768 |
154 |
20.1 |
(27) |
Panama, Honduras, Nicaragua |
Cross-sectional |
All HIV |
Symptomatic |
Inpatient |
IMMY GM EIA |
4453 |
1343 |
20.0 |
(28) | Trinidad | Cross-sectional | HIV | Asymptomatic | Outpatient | IMMY GM EIA + OIDx LFA | 280 | 280 | 6.4 |
*EIA, enzyme immunoessay; GM, galactomannan; HUA, histoplasma urine antigen; LFA, lateral flow assay. †All HIV refers to participants with HIV who were not stratified by CD4 or limited to CD4 counts <200, such as persons in advanced HIV cohorts. ‡Test manufacturers and types: MV, MiraVista Diagnostics EIA (https://miravistalabs.com); IMMY Alpha and GM EIAs (https://www.immy.com); OIDx, Optimum Imaging Diagnostics LFA (https://optimumimaging.com).
References
- Adenis AA. AIDS-related histoplasmosis in Latin America [abstract]. Med Mycol. 2018;56(Suppl 2):S7.
- Samayoa B, Roy M, Cleveland AA, Medina N, Lau-Bonilla D, Scheel CM, et al. High mortality and coinfection in a prospective cohort of human immunodeficiency virus/acquired immune deficiency syndrome patients with histoplasmosis in Guatemala. Am J Trop Med Hyg. 2017;97:42–8. DOIPubMedGoogle Scholar
- Adenis AA, Valdes A, Cropet C, McCotter OZ, Derado G, Couppie P, et al. Burden of HIV-associated histoplasmosis compared with tuberculosis in Latin America: a modelling study. Lancet Infect Dis. 2018;18:1150–9. DOIPubMedGoogle Scholar
- Ashraf N, Kubat RC, Poplin V, Adenis AA, Denning DW, Wright L, et al. Re-drawing the maps for endemic mycoses. Mycopathologia. 2020;185:843–65. DOIPubMedGoogle Scholar
- Adenis A, Nacher M, Hanf M, Basurko C, Dufour J, Huber F, et al. Tuberculosis and histoplasmosis among human immunodeficiency virus-infected patients: a comparative study. Am J Trop Med Hyg. 2014;90:216–23. DOIPubMedGoogle Scholar
- Villareal K, Price A, Pasqualotto AC, Bahr NC. The current and future states of diagnostic tests for histoplasmosis with a focus on people with HIV and disseminated histoplasmosis. J Fungi (Basel). 2023;9:
793793 . DOIPubMedGoogle Scholar - Martínez-Gamboa A, Niembro-Ortega MD, Torres-González P, Santiago-Cruz J, Velázquez-Zavala NG, Rangel-Cordero A, et al. Diagnostic accuracy of antigen detection in urine and molecular assays testing in different clinical samples for the diagnosis of progressive disseminated histoplasmosis in patients living with HIV/AIDS: A prospective multicenter study in Mexico. PLoS Negl Trop Dis. 2021;15:
e0009215 . DOIPubMedGoogle Scholar - Cáceres DH, Gómez BL, Tobón ÁM, Chiller TM, Lindsley MD. Evaluation of OIDx Histoplasma urinary antigen EIA. Mycopathologia. 2022;187:129–31. DOIPubMedGoogle Scholar
- Torres-González P, Niembro-Ortega MD, Martínez-Gamboa A, Ahumada-Topete VH, Andrade-Villanueva J, Araujo-Meléndez J, et al. Diagnostic accuracy cohort study and clinical value of the Histoplasma urine antigen (ALPHA Histoplasma EIA) for disseminated histoplasmosis among HIV infected patients: A multicenter study. PLoS Negl Trop Dis. 2018;12:
e0006872 . DOIPubMedGoogle Scholar - Theel ES, Jespersen DJ, Harring J, Mandrekar J, Binnicker MJ. Evaluation of an enzyme immunoassay for detection of Histoplasma capsulatum antigen from urine specimens. J Clin Microbiol. 2013;51:3555–9. DOIPubMedGoogle Scholar
- Goldet G, Howick J. Understanding GRADE: an introduction. J Evid Based Med. 2013;6:50–4. DOIPubMedGoogle Scholar
- Caceres DH, Knuth M, Derado G, Lindsley MD. Diagnosis of progressive disseminated histoplasmosis in advanced HIV: a meta-analysis of assay analytical performance. J Fungi (Basel). 2019;5:76. DOIPubMedGoogle Scholar
- Abdallah W, Myint T, LaRue R, Minderman M, Gunn S, Wheat LJ, et al. Diagnosis of histoplasmosis using the MVista Histoplasma galactomannan antigen qualitative lateral flow-based immunoassay: a multicenter study. Open Forum Infect Dis. 2021;8:ofab454.